{"id":8243,"date":"2020-07-15T11:27:17","date_gmt":"2020-07-15T18:27:17","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=8243"},"modified":"2021-04-01T11:28:13","modified_gmt":"2021-04-01T18:28:13","slug":"an-mrna-vaccine-against-sars-cov-2-preliminary-report","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/07\/15\/an-mrna-vaccine-against-sars-cov-2-preliminary-report\/","title":{"rendered":"An MRNA Vaccine against SARS-CoV-2 \u2014 Preliminary Report"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"34\" data-aria-posinset=\"2019\" data-aria-level=\"1\"><span data-contrast=\"auto\">The candidate vaccine mRNA-1273 was shown to induce antibody and T-cell\u00a0<\/span><span data-contrast=\"auto\">immune responses in all participants<\/span><span data-contrast=\"auto\">\u00a0(n=45).<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"34\" data-aria-posinset=\"2019\" data-aria-level=\"1\"><span data-contrast=\"auto\">Jackson et al.\u00a0<\/span><span data-contrast=\"auto\">conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, to test the candidate vaccine mRNA-1273 encoding the stabilized prefusion of SARS-CoV-2 spike protein. Participants received two vaccinations, 28 days apart\u00a0in\u00a0three dose groups.<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"34\" data-aria-posinset=\"2019\" data-aria-level=\"1\"><span data-contrast=\"auto\">After the first vaccination, antibody responses were higher among those who received the higher dose. After the second vaccination, the titers\u00a0increased\u00a0and all participants had\u00a0serumneutralizing\u00a0activity. No trial-limiting safety concerns were identified.\u00a0<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"none\">Jackson et al. (July 14, 2020). An MRNA Vaccine against SARS-CoV-2 \u2014 Preliminary Report. New England Journal of Medicine.\u00a0<\/span><\/i><a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2022483\"><span data-contrast=\"none\">https:\/\/doi.org\/10.1056\/NEJMoa2022483<\/span><\/a><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559685&quot;:720,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The candidate vaccine mRNA-1273 was shown to induce antibody and T-cell\u00a0immune responses in all participants\u00a0(n=45).\u00a0 Jackson et al.\u00a0conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, to test the candidate vaccine mRNA-1273 encoding the stabilized prefusion of SARS-CoV-2 spike protein. Participants received two vaccinations, 28 days apart\u00a0in\u00a0three dose groups.\u00a0 After the first vaccination,&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/07\/15\/an-mrna-vaccine-against-sars-cov-2-preliminary-report\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[31],"class_list":["post-8243","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=8243"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8243\/revisions"}],"predecessor-version":[{"id":8244,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8243\/revisions\/8244"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=8243"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=8243"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=8243"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=8243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}